What You Should Know:
- The Partnership: Viz.ai, a major player in AI-powered care coordination, has partnered with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.
- The Clinical Problem: Cardiac amyloidosis (specifically ATTR-CM and AL) is a progressive, often fatal condition where misfolded proteins deposit in the heart muscle. Because its symptoms mimic generalized heart failure, it is chronically underdiagnosed, causing patients to miss the window for life-saving interventions.
- The Technology Stack: Viz.ai is building a specialized “AI Care Pathway” that runs in the background of a hospital’s IT system. It utilizes Us2.ai (an FDA-cleared echocardiography AI algorithm), deep EHR connectivity, and generative AI to automatically analyze standard, routine echocardiograms.
- The Workflow Fix: Instead of waiting for a physician to specifically suspect amyloidosis, the AI flags subtle imaging and clinical red flags on its own. It then triggers an automated, coordinated workflow for confirmatory testing, specialist referral, and follow-up.
- The Rollout: The pathway will launch as a multi-site pilot study to generate real-world evidence on its ability to reduce time-to-treatment before rolling out to the 2,000+ hospitals already using the Viz platform.
